Top Story

Moderate-to-severe menopausal vasomotor symptoms increased hip fracture risk

December 18, 2014

Women with moderate-to-severe vasomotor symptoms during menopause showed lower bone mineral density and higher rates of hip fracture than women without the symptoms, according to research published in The Journal of Clinical Endocrinology & Metabolism.

“Compared with women who did not have hot flashes at the beginning of the study, women who reported having hot flashes at the beginning of the study had almost double the risk of hip fractures,” Carolyn J. Crandall, MD, of David Geffen School of Medicine, University of California, Los Angeles, told Endocrine Today. “Women who reported hot flashes also had lower bone density at the lumbar spine and the hip.”

In the Journals

Diabetes, metabolic disorders linked to urban stressors

December 18, 2014
Diabetes and metabolic disorders may be more common among people in developing nations who live in cities vs. those who remain in rural areas because of increased stress…
Health Care Legislative and Regulatory Update

New year, new code: How to get paid for chronic care management in 2015, part 1

December 18, 2014
From international law firm Arnold & Porter LLP comes a timely column that provides views on current regulatory and legislative topics that weigh on the minds of today’s…
FDA News

FDA announces members of its Pharmacy Compounding Committee

December 18, 2014
The FDA has announced the roster of its new Pharmacy Compounding Advisory Committee, the agency announced in a press release. The 14-member committee includes a lineup…

Top honors awarded to web resources from the Endocrine Society

December 17, 2014
Top honors in the Summer/Fall 2014 Web Health Awards Competition have been awarded to two of the Endocrine Society’s consumer health education websites, according…
More News Headlines »
CME
Acromegaly: Challenges in Diagnosis - Part 2 of 5

Acromegaly: Challenges in Diagnosis - Part 2 of 5

This activity is supported by an educational grant from Genentech.

The diagnosis of acromegaly is often not made until 7 to 10 years after symptom onset. Contributing factors include low…
More »
Meeting News Coverage Video
thumbnail for video 3890508474001

Lenvatinib, sorafenib may significantly impact treatment of differentiated thyroid cancer

November 13, 2014
Marcia S. Brose, MD, PhD, associate professor at the University of Pennsylvania and director of the thyroid cancer…
More »
CME
Acromegaly Cases

Acromegaly Cases: Expert Insights into Diagnosis and Emerging Treatment Options – Part 5 of 5

This activity is supported by an educational grant from Genentech.

Acromegaly is a rare chronic disorder that is typically caused by excessive growth hormone secretion, and is…
More »
morganatic-roan